Therapeutic potential of small interfering RNA for brain diseases

Therapeutic Ribonucleic Acids in Brain Tumors

Volumn , Issue , 2009, Pages 275-295

  Lovett Racke, Amy E ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054752094     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-00475-9_13     Document Type: Chapter

References (97)

1. Ahmed Z, Suggate EL, Brown ER et al (2006) Schwann cell-derived factor-induced modulation of the NgR/p75NTR/EGFR axis disinhibits axon growth through CNS myelin in vivo and in vitro. Brain 129:1517-1533.
2. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol Ther 104:29-45.
3. Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977.
4. Boado RJ (2007) Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 24:1772-1787.
5. Buffo A, Zagrebelsky M, Huber AB et al (2000) Application of neutralizing antibodies against NI-35/250 myelin-associated neurite growth inhibitory proteins to the adult rat cerebellum induces sprouting of uninjured Purkinje cell axons. J Neurosci 20:2275-2286.
6. Chabas D, Baranzini SE, Mitchell D et al (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731-1735.
7. Chen ZJ, Kren BT, Wong PY et al (2005) Sleeping Beauty-mediated down-regulation of huntingtin expression by RNA interference. Biochem Biophys Res Commun 329:646-652.
8. Chu TC, Twu KY, Ellington AD et al (2006) Aptamer mediated siRNA delivery. Nucleic Acids Res 34:e73.
9. Corder EH, Saunders AM, Strittmatter WJ et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923.
10. Cua DJ, Sherlock J, Chen Y et al (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421:744-748.
11. Denovan-Wright EM, Rodriguez-Lebron E, Lewin AS et al (2008) Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo. Neurobiol Dis 29:446-455.
12. Di Figlia M, Sena-Esteves M, Chase K et al (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 104:17204-17209.
13. Ding H, Schwarz DS, Keene A et al (2003) Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2:209-217.
14. Doi Y, Oki S, Ozawa T et al (2008) Orphan nuclear receptor NR4A2 expressed in T cells from multiple sclerosis mediates production of inflammatory cytokines. Proc Natl Acad Sci USA 105:8381-8386.
15. Duyao MP, Auerbach AB, Ryan A et al (1995) Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269:407-410.
16. Elman J, Thonberg H, Ljumberg K et al (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439-447.
17. Fan QW, Weiss WA (2005) RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene 24:829-837.
18. Fawcett JW, Asher RA (1999) The glial scar and central nervous system repair. Brain Res Bull 49:377-391.
19. Ferber IA, Brock S, Taylor-Edwards C et al (1996) Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156:5-7.
20. Fire A, Xu S, Montgomery MK, Kostas SA et al (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.
21. Fountaine TM, Wade-Martins R (2007) RNA interference-mediated knockdown of alphasynuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 85:351-363.
22. George J, Banik NL, Ray SK (2008) Bcl-2 siRNA augments taxol mediated apoptotic death in human glioblastoma U138MG and U251MG cells. Neurochem Res. Doi:10.1007/s11064-008-9659-z.
23. Goate A, Chartier-Harlin M-C, Mullan M et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349:704-706.
24. Gocke AR, Cravens PD, Ben L et al (2007) T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 178:1341-1348.
25. Gondi CS, Lakka SS, Dinh DH et al (2004) RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 23:8486-8496.
26. Gondi CS, Lakka SS, Dinh DH et al (2007) Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. Clin Cancer Res 13:4051- 4060.
27. Grand-Pre T, Nakamura F, Vartanian T et al (2000) Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 403:439-444.
28. Grand-Pre T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417:547-551.
29. Grzelinski M, Urban-Klein B, Martens T et al (2006) RNA interference-mediated gene silencing of pleiotrophin through polyethlenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 17:751-766.
30. Habig K, Walter M, Poths S et al (2008) RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9:83-94.
31. Hamilton AJ, Baulcombe DC (1999) A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 286:950-952.
32. Harper SQ, Staber PD, He X et al (2005) RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102:5820-5825.
33. Hartung HP, Bar-Or A, Zoukos Y (2004) What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 251(suppl 5):v12-v29.
34. Hengst U, Cox LJ, Macosko EZ et al (2006) Functional and selective RNA interference in developing axons and growth cones. J Neurosci 26:5727-5732.
35. Hong CS, Goins WF, Goss JR et al (2006) Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther 13:1068-1079.
36. Houlden H, Baker M, Morris HR et al (2001) Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56:1702-1706.
37. Juliano RL (2005) Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr Opin Mol Ther 7:132-136.
38. Kang CS, Pu PY, Li YH et al (2005) An in vitro study on the suppressive effect of glioma cell growth induced by plasmid-based small interference RNA (siRNA) targeting human epidermal growth factor receptor. J Neurooncol 74:267-273.
39. Kao SC, Krichevsky AM, Kosik KS et al (2004) BACE1 suppression by RNA interference in primary cortical neurons. J Biol Chem 279:1942-1949.
40. Kargiotis O, Chetty C, Gondi CS et al (2008) Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene 27:4830-4840.
41. Kaun CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96.
42. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas from concept to clinical diagnosis. Neuro-oncol 1:44-51.
43. Kumar P, Ban HS, Kim SS et al (2008) T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134:577-586.
44. Lakka SS, Gondi CS, Dinh DH et al (2005) Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth and angiogenesis in gliomas. J Biol Chem 280:21882-21892.
45. Langrish CL, Chen Y, Blumenschein M et al (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201:233-240.
46. Le Mercier M, Mathieu V, Haibe-Kains B et al (2008) Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol 67:456-469.
47. Lewis J, Dickson DW, Lin WI et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491.
48. Locatelli F, Corti S, Papadimitriou D et al (2007) Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann Neurol 62:81-92.
49. Lovett-Racke AE, Rocchini AE, Choy J et al (2004) Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 21:719-731.
50. Luo Y, Bolon B, Kahn S et al (2001) Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231-232.
51. Luo HM, Deng H, Xiao F et al (2004) Down-regulation amyloid beta-protein 42 production by interfering with transcript of presenilin 1 gene with siRNA. Acta Pharmacol Sin 25:1613-1618.
52. Machida Y, Okada T, Kurosawa M et al (2006) rAAV-mediated shRNA ameliorated neuropathology in Huntingtin disease model mouse. Biochem Biophys Res Commun 343:190-197.
53. Maxwell MM, Pasinelli P, Kazantsev AG et al (2004) RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci USA 101:3178-3183.
54. Miller VM, Xia H, Marrs GL et al (2003) Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 100:7195-7200.
55. Miller VM, Gouvion CM, Davidson BL et al (2004) Targeting Alzheimer's disease genes with RNA interference: An efficient strategy for silencing mutant alleles. Nucleic Acids Res 32:661-668.
56. Miller TM, Kaspar BK, Kops GJ et al (2005) Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann Neurol 57:773-776.
57. Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNA. Nat Biotechnol 23:1002-1007.
58. Mullan M, Crawford F, Axelman K et al (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta amyloid. Nat Genet 1:345-347.
59. Muratovska A, Ecles MR (2004) Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558:63-68.
60. Napoli C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 2:279-289.
61. Nasir J, Floresco SB, O'Kusky JR et al (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823.
62. Nawrot B (2004) Targeting BACE with small inhibitory nucleic acids - A future for Alzheimer's disease therapy. Acta Biochem Pol 51:431-444.
63. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37:S9-S15.
64. Niola F, Evangelisti C, Campangnolo L et al (2006) A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 5:174-179.
65. Oddo S, Caccamo A, Shepherd JD et al (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39:409-421.
66. Olsson T (1992) Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol 40:211-218.
67. Outeiro TF, Kontopoulos E, Altmann SM et al (2007) Sirtuin 2 inhibitors rescue alpha-synucleinmediated toxicity in models of Parkinson's disease. Science 317:516-519.
68. Pals P, Lincoln S, Manning J et al (2004) Alpha-synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 56:591-595.
69. Panitch HS, Hirsch RL, Haley AS et al (1987) Exacerbation of multiple sclerosis in patients with gamma interferon. Lancet 1:893-895.
70. Polymeropoulos MH, Lavedan C, Leroy E et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
71. Prinjha R, Moore SE, Vinson M et al (2000) Inhibitor of neurite outgrowth in humans. Nature 403:383-384.
72. Pu P, Kang C, Zhang Z et al (2006) Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Technol Cancer Res Treat 5:271-280.
73. Purow BW, Haque RM, Noel MW et al (2005) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65:2353-2363.
74. Racke MK, Bonomo A, Scott DE et al (1994) Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 180:1961-1966.
75. Racke MK, Burnett D, Pak SH et al (1995) Retinoid treatment of experimental allergic encephalomyelitis: IL-4 production correlates with improved disease course. J Immunol 154:450-458.
76. Ralph GS, Radcliffe PA, Day DM et al (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11:429-433.
77. Raoul C, Abbas-Terki T, Bensadoun JC et al (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11:423-428.
78. Romano N, Macino G (1992) Quelling: Transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences. Mol Microbiol 6:3343-3353.
79. Saito Y, Yokota T, Mitani T et al (2005) Transgenic small interfering RNA cells halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem 280:42826-42830.
80. Sapru MK, Yates JW, Hogan S et al (2006) Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198:382-390.
81. Saydam O, Glauser DL, Heid I et al (2005) Herpes simplex virus 1 amplicon vector-mediated siRNA targeting epidermal growth factor receptor inhibits growth of human glioma cells in vivo. Mol Ther 12:803-812.
82. Schwarz DS, Ding H, Kennington L et al (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2:e140.
83. Singer O, Marr RA, Rockenstein E et al (2005) Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8:1343-1349.
84. Singleton AB, Farrer M, Johnson J et al (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302:841.
85. Thakker DR, Natt F, Husken D et al (2004) Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain using nonviral RNA interference. Proc Natl Acad Sci USA 101:17270-17275.
86. Tummalapalli P, Gondi CS, Dinh DH et al (2007) RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol 31:5-17.
87. Van der Krol AR, Mur AL, Beld M et al (1990) Flavanoid genes in petunia: Addition of a limited number of gene copies may lead to a suppression of gene expression. Plant Cell 2:291-299.
88. Wang H, Ghosh A, Baigude H et al (2008) Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem 283:15845-15852.
89. Willenborg DO, Fordham S, Bernard CC et al (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte-induced autoimmune encephalomyelitis. J Immunol 157:3223-3227.
90. Xia H, Qinwen M, Eliason SL et al (2004) RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 10:816-820.
91. Xia XG, Zhou H, Zhou S et al (2005) An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu, Zn superoxide dismutase. J Neurochem 92:362-367.
92. Xia X, Zhou H, Huang Y et al (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 23:578-586.
93. Yokota T, Miyagishi M, Hino T et al (2004) siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme. Biochem Biophys Res Commun 314:283-291.
94. Zeitlin S, Liu JP, Chapman DL et al (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat Genet 11:155-163.
95. Zhang Y, Zhang Y, Bryant J et al (2004) Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10:3667-3677.
96. Zhu Y, Hoell P, Ahlemeyer B et al (2007) Implications of PTEN in production of reactive oxygen species and neuronal death in in vitro models of stroke and Parkinson's disease. Neurochem Int 50:507-516.
97. Zukiel R, Nowak S, Wyszko E et al (2006) Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther 5:1002-1007.